Compare BRCC & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRCC | KZIA |
|---|---|---|
| Founded | 2014 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.6M | 161.5M |
| IPO Year | N/A | 1999 |
| Metric | BRCC | KZIA |
|---|---|---|
| Price | $1.24 | $11.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $2.63 | ★ $17.67 |
| AVG Volume (30 Days) | 535.6K | ★ 2.0M |
| Earning Date | 11-03-2025 | 12-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $391,401,000.00 | $1,199,108.00 |
| Revenue This Year | $3.12 | N/A |
| Revenue Next Year | $11.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.17 | $2.86 |
| 52 Week High | $3.34 | $21.00 |
| Indicator | BRCC | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 45.95 | 51.53 |
| Support Level | $1.22 | $11.75 |
| Resistance Level | $1.28 | $17.40 |
| Average True Range (ATR) | 0.05 | 2.71 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 43.33 | 35.08 |
BRC Inc is a veteran-controlled company that serves premium coffee, content, and merchandise to active military, veterans, and first responders. It is committed to producing great coffee that consumers love, and high-quality merchandise that enables its community to showcase its brand. Its omnichannel distribution has three components: Direct to Consumer channel includes its e-commerce business, through which consumers order products online and products are shipped to them, Its wholesale channel includes products sold to an intermediary such as convenience, grocery, drug, and mass merchandise stores, who in turn sell those products to consumers, and Outpost channel includes revenue from its Company-operated and franchised Black Rifle Coffee retail coffee shop locations.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.